ArticleObesity surgery2025
The Effect of Cholecystectomy on Weight Loss after Metabolic Bariatric Surgery.
Article in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBile acids (BAs) play a crucial role in metabolic regulation and weight loss, especially in the context of metabolic bariatric surgery (MBS). BAs contribute to the body's hormonal response to meals, influencing glucose metabolism, lipid regulation, and energy expenditure. Changes in BA homeostasis following MBS have been associated with metabolic improvements. Conversely, cholecystectomy (CCx) disrupts the rhythmic secretion of bile and has been linked to metabolic disturbances, including non-alcoholic fatty liver disease and metabolic syndrome. The impact of CCx performed prior to or concurrently with MBS on weight loss remains unclear.
methodsWe conducted a retrospective analysis of MBS patients (2016-2023), categorizing them by CCx status and type of primary MBS. Weight loss outcomes were assessed at 30 days, 6 months, and 1 year postoperatively. Linear mixed models were used to evaluate percent total weight loss (%TWL), adjusting for age, sex, BMI, and comorbidities.
resultsAmong 2437 patients, 22.2% had a history of CCx (21.1% before MBS, 1.1% concurrent). Roux-en-Y gastric bypass (RYGB) patients with CCx achieved significantly greater %TWL (32.7% vs. 29.5%; p = 0.002) and dBMI (15.2 ± 6.7 vs. 13.1 ± 4.6, p = 0.001) at 1 year compared to those without CCx. No significant differences in %TWL or dBMI were observed in sleeve gastrectomy patients.
conclusionsRYGB patients with prior or concurrent CCx experienced greater weight loss than those without CCx. Further research is needed to clarify the metabolic impact of CCx on MBS and the underlying physiological mechanisms.
Indexed as
Identifiers
39934521What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.